Glaucoma patients more likely to suffer from hysteria

Article

Patients with open angle glaucoma (OAG) are more likely to have abnormal Minnesota Multiphasic Personality Inventory-2 (MMPI-2) scores in the areas that focus upon concerns of somatic complaints and poor health.

Patients with open angle glaucoma (OAG) are more likely to have abnormal Minnesota Multiphasic Personality Inventory-2 (MMPI-2) scores in the areas that focus upon concerns of somatic complaints and poor health, according to a study published in the December 2007 issue of the Journal of Glaucoma.

Michele Lim from the University of California, Davis, Sacramento, California, USA and colleagues conducted a study to characterize the personality profile of glaucoma subjects. A total of 108 subjects, 56 with OAG and 52 controls, were given the MMPI-2 test, in addition to performing automated perimetry.

Subjects with OAG had significantly higher hypochondriasis, hysteria and health concern scores than the control subjects. OAG subjects also had a significantly greater frequency of clinically abnormal scores for hysteresis and health concerns. Multivariate analysis of variance revealed that hypochondriasis, hysteria and health concerns scores were related to the number of systemic medications used.

The researchers believe that the use of systemic medications may be a constant reminder of illness, perhaps explaining the higher MMPI-2 scores in patients with OAG.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.